[ACCEL Stars]
ACCELStars, a medical sleep tech company from the University of Tokyo School of Medicine, and Neuroceuticals enter into a strategic business alliance with the aim of building a next-generation medical device industry ecosystem.
*View in browser* *ACCEL Stars*
Press release: May 7, 2024
**
ACCELStars, a medical sleep tech company from the University of Tokyo School of Medicine, and Neuroceuticals enter into a strategic business alliance with the aim of building a next-generation medical device industry ecosystem.
*Strengthening collaboration between the two companies to promote the creation of an ecosystem that produces innovative medical devices from within Japan*
Medical Sleep from the University of Tokyo School of Medicine Tech startups ACCELStars Co., Ltd. (hereinafter referred to as AS) (Headquarters: Kurume City, Fukuoka Prefecture, Representative Director and CEO: Sadao Miyahara) and Neuroceuticals Co., Ltd. (hereinafter referred to as NCI) (Headquarters in Bunkyo-ku, Tokyo) (Representative Director and President Shinya Miike) is pleased to announce that we have entered into a strategic business alliance to build a next-generation medical device industry ecosystem in Japan.
AS is a startup that promotes the development of highly accurate sleep determination algorithms and medical device development. In April 2024, AS’s first medical device, the Actigraph Sensor, a
wristwatch-type wearable device capable of highly accurate sleep/wake determination, will be launched.
ACCEL
We have started selling “ATRIA”. Normally, startups have difficulty securing resources and managing the hardware for medical devices, which is difficult to manage.
In addition, NCI aims to promote the horizontal division of labor in medical device development, which has become a standard around the world, in Japan, and has promoted the development and support of various medical devices, and has achieved many results.
The two companies have decided to form a strategic business alliance, complementing each other’s strengths and weaknesses, in order to continue developing innovative medical devices into the future.
Specifically, in domestic medical device development, we are working on the highly specialized and difficult approval process, conducting clinical research and clinical trials, accumulating knowledge in technology development, and ensuring that highly capable and specialized human resources continue to be highly motivated. We will continue to actively collaborate with the aim of creating a system that allows employees to continue working in a positive manner. Through these efforts, we aim to build an ecosystem for the medical device industry where innovative medical devices continue to be produced in Japan at a rapid pace.
■AS overview
Company name ACCELStars Co., Ltd.
Representative Sadao Miyahara
Head Office: 1-1 Centennial Park, Kurume City, Fukuoka Prefecture Tokyo Office 205, University of Tokyo Entrepreneur Plaza, 7-3-1 Hongo, Bunkyo-ku, Tokyo
URL https://www.accelstars.com/
■ NCI overview
Company name Neuroceuticals Co., Ltd.
Representative Shinya Miike
Head Office Hongo TK Building 6F, 1-28-10 Hongo, Bunkyo-ku, Tokyo URL https://www.nci-md.com/
Inquiries regarding this press release and requests for interviews ACCELStars Co., Ltd. Public Relations
e-mail: press@accelstars.com
*About details about this release*
https://prtimes.jp/main/html/rd/p/000000035.000082124.html
Unsubscribe HTML email
Copyright © PR TIMES Corporation All Rights Reserved.